Facelift in Stamford Connecticut
As we become older the gravity, sun exposure and everyday stress leave their marks on our faces. Wrinkles appear between the nose and the mouse, the skin becomes lose and drop below the jaw line and extra fat and skin accumulates around the neck. Facelift cannot stop the aging process but it can "turn back time" by removing extra skin and fat and straitening the muscles.
The ideal candidates for the procedure are patients with skin of the face and neck that started to drop but still has its elasticity.
The operation last from 3-7 hours (it can be longer if additional procedures are done). Some surgeons prefer to work on each side at a time and some do both sides simultaneously. The placement of the cuts and the magnitude of the operation depend on face structure and the correction required. The cut usually starts on the forehead goes in front of the ear and behind the ear lobe, additional cut below the chin is made to repair the neck. The surgeon separates the skin from the fat, removes the extra fat, strengthens the muscles and returns the fat pockets where they use to be. Afterwards he stretches the skin, cuts the extra and closes with sutures. A drainage tube usually left from both sides to draine secretions and blood and the face is bandaged for the first 24 hours.
Every operation has its risks although not common those include, bleeding, infection, damage to facial nerves (usually temporal), face asymmetry and delayed healing. Patients who smoke have higher rates of delayed healing.
There may be pain or uncomfortable felling after the recovery that can be treated with painkillers. A sensation of ants crawling usually disappears after weeks or a month after the surgery. Bandages are removed after a day or two and your face may look swollen. Red or pale with bleeding spots, you must remember that those will disappear after few days or weeks.
You can get out of bed after 24 hours but you should avoid any efforts for at least a week to help the healing process. You should avoid alcohol, hot tubs and saunas for at least a month. Most of the patients feel disappointed at first, their face look and feel strange but after a few weeks the scars will heal and you'll be able to see the final results. Many patients return to work after 3 weeks. Sometimes you may need to use make up to blur the hemorrhage spots.
More Stamford info...
Stamford Get in
By plane - Stamford is about 45 minutes away from New York's La Guardia Airport, about an hour from JFK Airport, and about 1 hour 15 minutes away from Newark Liberty International Airport in New Jersey. Connecticut Limo, http://www.ctlimo.com/ is a good shuttle service to get to Stamford. Also, Westchester County Airport (HPN) is about 15-20 minutes from Stamford.
By train - Amtrak's trains make stops at Stamford. Also, Metro North commuter trains come to and from New York City's Grand Central terminal. Off-peak, there is at least one express train (about 45 minutes) and a couple of local trains (about 1 hour 10 minutes). More trains are available during peak hours.
By car - I-95 is the major interstate highway that goes through downtown Stamford. Merritt Parkway goes parallel to I-95 about 5 miles North.
Stamford Get around Having a car is a must unless you plan on restricting yourself to downtown Stamford and destinations reachable by bus. Rental cars can be easily arranged. Stamford has several bus routes, some of which go to nearby towns in Connecticut and even Westchester County, New York. Click here for more information. There are several taxi companies serving Stamford. Among them are Stamford Taxi, Tel. 1-203-325-2611, and Eveready, Tel. 1-203-655-8779
Plastic Surgery News...
- Objectives To present a new classification of 15 anatomical lip zones used to direct placement of injectable fillers during lip augmentation and to evaluate the new classification's ability to customize lip contour and size.
Methods Study participants were consecutive patients presenting to a facial plastic and reconstructive surgery practice for injectable lip augmentation with a nonanimal-sourced stabilized hyaluronic acid (Restylane; Medicis Aesthetic Inc, Scottsdale, Arizona). A nonrandomized, prospective case series.
Results A total of 137 treatments were performed on lips of 66 patients. The mean (SD) satisfaction score was 4.5 (0.6) on an integral scale of 1 (dissatisfied) to 5 (most satisfied). The mean (SD) persistence until lips returned to preoperative appearance based on patient subjective evaluation was 4.9 (1.5) months. Patients were free of adverse effects.
Conclusions Using a new classification of lip anatomical zones to direct the injection of a nonanimal-sourced stabilized hyaluronic acid has increased my ability to better control lip shape and size in lip augmentation. This technique was met with high patient satisfaction and no adverse effects. Persistence of injected nonanimal-sourced stabilized hyaluronic acid was similar to that seen in other studies. (Source: Archives of Facial Plastic Surgery)
- The National Institute for Health and Clinical Excellence (NICE) has published an appraisal consultation document (ACD – draft guidance) on the use of alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. The guidance recommends (direct from source):
1.1 Alendronate is recommended as a treatment option for the secondary prevention of osteoporotic fragility fractures in postmenopausal women who have a T-score of -2.5 SD or below. In women aged 75 years or older, a DXA scan may not be required if the responsible clinician considers it to be clinically inappropriate or unfeasible.
When the decision has been made to initiate treatment with alendronate, the preparation prescribed should be chosen on the basis of the lowest acquisition cost available.
1.2 Risedronate and etidronate are recommended as alternative treatment options for the secondary prevention of osteoporotic fragility fractures in postmenopausal women:
• who are unable to comply with the special instructions for the administration of alendronate, have a contraindication to, or are intolerant of alendronate (as defined in section 1.7) and
• who also have a T-score, age and number of independent clinical risk factors for fracture (see section 1.5) - please refer to table in the ACD for T-scores (SD) at (or below) which risedronate or etidronate is recommended.
1.3 Raloxifene and strontium ranelate are recommended as alternative treatment options for the secondary prevention of osteoporotic fragility fractures in postmenopausal women:
• who are unable to comply with the special instructions for the administration of alendronate and risedronate, or who have a contraindication to or are intolerant of alendronate and risedronate (as defined in section 1.6) and
• who also have a T-score, age and number of independent clinical risk factors for fracture (see section 1.5) - please refer to table in the ACD for T-scores (SD) at (or below) which raloxifene or strontium ranelate is recommended.
1.4 Teriparatide is recommended as an alternative treatment option for the secondary prevention of osteoporotic fragility fractures in postmenopausal women:
• who are unable to take alendronate and risedronate, have a contraindication to, or are intolerant of alendronate and risedronate (as defined in section 1.6) or who have a contraindication to, or are intolerant of strontium ranelate (as defined in section 1.7) and
• who are 65 years or older and have an extremely low BMD (with a T-score of -4 SD or below), or a very low BMD (with a T-score of -3.5 SD or below) plus multiple fractures (that is, more than two), or who are aged 55-64 years and have a T-score of -4 SD or below plus multiple fractures (that is, more than two).
1.5 For the purposes of this guidance, independent clinical risk factors for fracture to be considered are: parental history of hip fracture, alcohol intake of 4 or more units per day, and severe, long-term rheumatoid arthritis.
1.6 For the purposes of this guidance, intolerance of alendronate and risedronate is defined as persistent upper gastrointestinal disturbance that is sufficiently severe to warrant discontinuation of treatment and that occurs even though the instructions for administration have been followed correctly.
1.7 For the purpose of this guidance, intolerance of strontium ranelate is defined as persistent nausea or diarrhoea, either of which warrants discontinuation of treatment.
1.8 Women who are currently receiving treatment with one of the drugs covered by this guidance, but for whom therapy would have not been recommended according to sections 1.1 to 1.4, should have the option to continue therapy until they and their clinicians consider it appropriate to stop.
The key dates for this appraisal are:
Closing date for comments: 23 April 2008
Second Appraisal Committee meeting: 01 May 2008